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Opsonophagocytic killing activitya b s t r a c t
Background: Following primary vaccination of adults P65 years of age with 23-valent pneumococcal
polysaccharide vaccine (PPSV23), immune responses increase and thereafter appear to decrease over
time. With increased life expectancy worldwide, revaccination with PPSV23 may be required for
continued protection of the elderly population against pneumococcal disease. The present study
evaluated the immunogenicity and safety of revaccination with PPSV23 in the Japanese elderly.
Methods: Depending on prior history of PPSV23 vaccination, adults aged P70 years were given a first
dose (primary group; N = 81) or second dose (revaccination group; N = 161, at least 5 years after first
dose) of PPSV23 intramuscularly. Subjects were matched for gender, age, and number and type of
comorbidity across both groups. Blood samples were collected before and 4 weeks postvaccination to
measure serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic killing activity
(OPA) antibody titers to serotypes included in the vaccine. Injection-site and systemic adverse events
(AEs) were collected for 14 days postvaccination.
Results: Baseline serotype-specific IgG geometric mean concentrations (GMCs) and OPA geometric mean
titers (GMTs) were generally higher in subjects with a prior history of PPSV23 vaccination than in
PPSV23-naïve subjects. The levels of IgG GMCs and OPA GMTs after revaccination were generally
comparable to those observed after primary vaccination. Incidences of systemic AEs were comparable
between the 2 groups. Although incidences of injection-site AEs were higher following revaccination than
primary vaccination, the difference was not clinically significant as most AEs were mild to moderate in
intensity and resolved within 5 days after revaccination without treatment.
Conclusion: Revaccination with PPSV23 was well tolerated and associated with increases in
serotype-specific IgG concentrations and OPA titers in the elderly who received a prior PPSV23 dose at
least 5 years before. Revaccination with PPSV23 can be safely implemented in the elderly for continued
prevention against pneumococcal disease.
Clinical trial registry number: NCT02260882
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Worldwide, adults P65 years of age are at high risk for
pneumococcal disease. The risk is further increased for those with
underlying illnesses such as chronic heart disease, chronic lung
disease, and diabetes mellitus [1,2]. The 23-valent pneumococcal
polysaccharide vaccine (PPSV23) has been developed by Merck &
Co., Inc., Kenilworth, NJ and contains capsular polysaccharides
from 23 pneumococcal capsular types of Streptococcus pneumoniae.
Several observational and clinical studies have demonstrated the
effectiveness of PPSV23 in the prevention of pneumococcal disease
3876 K. Kawakami et al. / Vaccine 34 (2016) 3875–3881in adults including the elderly population [3–10], and PPSV23 is
indicated for the prevention of pneumococcal disease in adults
P50 years of age in many countries worldwide. In 2012–2013, ser-
otypes most frequently associated with invasive pneumococcal
disease (IPD) in Japanese adults included serotypes 3 (18.5%), 22F
(7.9%), 14 (7.5%), 19A (7.5%), 6C (7.5%), and to a lesser extend
serotypes 6B, 10A and 23F. Based on these results, the coverage
rate afforded by PPSV23 for all IPD cases was 72.2% [11]. In October
2014, Japan introduced PPSV23 in the national immunization
program for the prevention of pneumococcal disease for elderly
individuals aged P65 years. Recently a 13-valent pneumococcal
conjugate vaccine (PCV13) was approved in Japan for the
prevention of pneumococcal disease in adults aged P65 years,
but it is not included in the national immunization program.
Following PPSV23 vaccination, serotype-specific immunoglobu-
lin G (IgG) concentrations and opsonophagocytic killing activity
(OPA) titers increase and then decline over time, though these gen-
erally remain above pre-vaccination levels after 5 years [12–14].
Since decreases in serotype-specific IgG concentrations and OPA
titers may lead to an increased risk of pneumococcal disease,
revaccination may be required in order to provide continued
protection with increasing age.
Over the past 40 years, Japan has become an ageing society; in
2010, the average life expectancy after the age of 65 was 18.74 and
23.80 years for men and women, respectively [15]. The need for
revaccination with PPSV23 in the Japanese elderly individuals is
expected to increase in the near future. PPSV23 revaccination in
adults aged P65 years who received their first dose of PPSV23 at
least 5 years before is recommended by the Japanese Association
for Infectious Diseases [16]. Ohshima et al. evaluated the safety
and immunogenicity of a second dose of PPSV23 in 40 elderly
patients with chronic lung disease [17]. The present study was con-
ducted in order to confirm the acceptable safety and immuno-
genicity profiles of PPSV23 revaccination in a large cohort of the
Japanese elderly subjects, and to provide further evidence of the
value of revaccination in clinical practice.
2. Methods
2.1. Overall study design
This was a non-randomized, open-label, multicenter study
conducted at 5 sites (3 general hospitals and 2 clinics) between
November 2014 and May 2015 to evaluate the immunogenicity
and safety of revaccination with PPSV23 in the Japanese elderly
population. Subjects were enrolled into one of the following groups
in a 2:1 ratio: revaccination group (subjects who had a confirmed
record of prior PPSV23 vaccination at least 5 years before study
enrollment) or primary vaccination group (subjects with no prior
history of PPSV23 vaccination). Characteristics such as age, gender
and number and type of comorbidity (i.e., chronic heart disease:
hypertension, angina pectoris and atrial fibrillation; chronic lung
disease: asthma, chronic bronchitis and chronic obstructive
pulmonary disease; diabetes mellitus) were matched between
the two groups. Immunocompromised subjects, those receiving
immunosuppressive therapy such as systemic corticosteroids,
those with a history of vaccination with pneumococcal conjugate
vaccine, those with a history of pneumococcal disease (positive
culture from blood or other normally sterile site) and those who
were febrile (defined as an oral temperature P37.5 C) within
24 h before PPSV23 vaccination were excluded from the study.
PPSV23 (PneumovaxNP, Merck Sharp & Dohme Corp., a
subsidiary of Merck & Co., Inc., Kenilworth, NJ) contains 25 lg of
each capsular polysaccharide of the 23 types of pneumococci per
vial (0.5 mL) and was supplied by each study site. PPSV23 was
injected intramuscularly, and the site of injection was recorded.2.2. Study objectives
The primary immunogenicity objective was to demonstrate that
serotype-specific IgG GMCs to serotypes 3, 6B, and 23F measured
4 weeks after revaccination with PPSV23 were statistically greater
than those measured immediately before revaccination (baseline);
these serotypes were selected because they were most prevalent in
Japanese adults with IPD, associated with 16.4% (serotype 3), 14.9%
(serotype 6B), and 7.6% (serotype 23F) of all IPD cases during
2010–2011 [11]. Overall, serotype-specific IgG GMCs to 14
serotypes and serotype-specific OPA GMTs to 6 serotypes were
measured immediately before and after primary vaccination or
revaccination with PPSV23. The safety objective was to assess
injection-site and systemic adverse events (AEs) after vaccination
with PPSV23 in the primary vaccination and revaccination groups.
2.3. Measurements
Blood samples were collected before and 4 weeks following
vaccination with PPSV23, and serum samples were stored at
20 C until used for testing. For serotype-specific IgG, antibody
concentrations of 14 serotypes included in PPSV23 (serotypes 1,
3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) were
measured using pneumococcal electrochemiluminescence
(Pn ECL) assay [18]. Moreover, IgG concentration for serotype 6A,
which is not included in PPSV23, was measured to assess possible
cross-reactivity afforded by an immune response to serotype 6B,
which is included in PPSV23. OPA was measured for 6 serotypes
(3, 4, 6B, 14, 22F, and 23F) using multiplexed OPA (MOPA) assay
[19]. The Pn ECL and OPA testing were performed at PPD Vaccines
and Biologics Laboratory (Wayne, PA, USA) and at the University of
Alabama (Birmingham, AL, USA), respectively.
Injection-site and systemic AEs occurring within 14 days
postvaccination were collected. Deaths and other vaccine-related
serious adverse events (SAEs) were recorded throughout the study.
All subjects were asked to record any injection-site reaction and
daily body temperature (oral method) in a vaccine diary for 5
consecutive days postvaccination. Causal relationship between
the reported AEs and receipt of PPSV23 was assessed by the study
investigators.
2.4. Statistical analysis
For the analyses of immunogenicity in the revaccination group,
a one-sample t-distribution was used to obtain the mean and 95%
confidence interval (CI) of changes in IgG GMCs from baseline
(before revaccination) to 4 weeks after revaccination. Subse-
quently, the mean and 95% CI were back transformed to calculate
the corresponding point estimate and 95% CI for geometric mean
fold rise (GMFR). The statistical success criterion for demonstrating
greater IgG GMCs at 4 weeks after vaccination was that the lower
bound of the two-sided 95% CI for GMFR was >1.0 for all three
serotypes (3, 6B, and 23F). For immunogenicity analyses for other
serotypes in the primary vaccination and revaccination groups,
IgG GMCs and OPA GMTs were calculated in a similar manner at
baseline and 4 weeks after vaccination.
The safety was evaluated based on solicited injection-site AEs
(pain, erythema, and swelling) occurring from Days 1 to 5 after
vaccination, fever (P37.5 C, oral temperature) occurring from
Days 1 to 5 after vaccination, and any other injection site and
systemic AEs occurring from Days 1 to 14 after vaccination.
2.5. Ethical conduct
The present study was conducted in accordance with the
principles of Good Clinical Practice. The protocol and informed
K. Kawakami et al. / Vaccine 34 (2016) 3875–3881 3877consent forms were reviewed and approved by the institutional
review board at each study site. Written informed consent was
obtained from all subjects before initiation of any protocol-
specified study procedure.3. Results
3.1. Baseline characteristics and disposition of subjects
A total of 242 subjects (161 in the revaccination group and 81 in
the primary vaccination group) received a single dose of PPSV23. All
subjects completed the study. In the revaccination group, 94
subjects (58.4%) were women, and the mean age was 78.8 years.
Among revaccinated subjects, a total of 127 (78.9%), 53 (32.9%),
and 33 (20.5%) subjects had underlying chronic heart disease,
chronic lung disease and diabetes mellitus, respectively, and 63
subjects (39.1%) had at least two comorbidities. Only 19
revaccinated subjects (11.8%) had none of these major
comorbidities. Subject baseline characteristics were similar in both
vaccination groups with regard to gender, age, and presence of
comorbidities. The median time interval between primary
vaccination and revaccination with PPSV23 in the revaccination
group was 7 years (range, 5–11) (Table 1).
3.2. Immunogenicity
3.2.1. Serotype-specific IgG antibody
In the revaccination group, serotype-specific IgG GMCs to
serotypes 3, 6B, and 23F measured 4 weeks after revaccination
with PPSV23 were 0.49, 2.10, and 3.34 lg/mL, respectively. The
corresponding IgG GMFRs (95% CIs) for serotypes 3, 6B, and 23F
were 2.72 (2.35, 3.14), 2.27 (2.02, 2.55), and 2.40 (2.12, 2.72),
respectively. IgG GMCs for serotypes 3, 6B, and 23F measured
4 weeks after revaccination were significantly greater (P < 0.001)
than those measured immediately before revaccination, as the
lower bounds of the two-sided 95% CIs for IgG GMFR were >1.0
for all three serotypes (Table 2).
Baseline IgG GMCs to 14 serotypes included in PPSV23 were
higher in the revaccination group than in the primary vaccination




Subjects in population, N 161 81
Gender
Male, n (%) 67 (41.6) 35 (43.2)
Female, n (%) 94 (58.4) 46 (56.8)
Mean of age, years (SD) 78.8 (4.8) 78.2 (5.0)
70–74, n (%) 39 (24.2) 20 (24.7)
75–79, n (%) 57 (35.4) 29 (35.8)
80–84, n (%) 40 (24.8) 19 (23.5)
85–89, n (%) 25 (15.5) 13 (16.0)
Underlying medical condition
Chronic heart disease, n (%) 127 (78.9) 60 (74.1)
Chronic lung disease, n (%) 53 (32.9) 22 (27.2)
Diabetes mellitus, n (%) 33 (20.5) 23 (28.4)
Number of underlying medical condition
0, n (%) 19 (11.8) 10 (12.3)
1, n (%) 79 (49.1) 41 (50.6)
P2, n (%) 63 (39.1) 30 (37.0)
Interval between 1st and 2nd dose of PPSV23
Median, years 7.0 NA
Range, years 5–11 NA
SD, standard deviation; PPSV23, 23-valent pneumococcal polysaccharide vaccine.were significantly higher at 4 weeks after vaccination with PPSV23
than those at baseline in both vaccination groups, although IgG
GMCs at 4 weeks after vaccination with PPSV23 varied by
serotypes in both groups. IgG GMFRs at 4 weeks after vaccination
were significantly lower in the revaccination group than in the
primary vaccination group (nominal P < 0.05). Only the IgG GMC
for serotype 19A measured at 4 weeks after vaccination with
PPSV23 in the revaccination group was significantly lower than
that observed in the primary vaccination group (nominal
P = 0.039), but levels of serotype-specific IgG GMCs for the other
13 serotypes at 4 weeks after vaccination with PPSV23 were
numerically comparable in both primary vaccination and revacci-
nation groups (Table 2 and Fig. 1).
3.2.2. Serotype-specific functional OPA
Baseline serotype-specific OPA GMTs were greater in the
revaccination group than in the primary vaccination group.
Serotype-specific OPA GMTs to each of the 6 serotypes tested by
MOPA assay were significantly greater at 4 weeks after vaccination
with PPSV23 than those at baseline in both vaccination groups. Like-
wise, OPA GMFRs at 4 weeks after vaccination were significantly
lower in the revaccination group than in the primary vaccination
group (nominal P < 0.05). Only the OPA GMT for serotype 4 mea-
sured at 4 weeks after vaccinationwith PPSV23 in the revaccination
group was significantly lower than that observed in the primary
vaccination (nominal P = 0.005), but levels of serotype-specific
OPA GMTs for the other 5 serotypes measured at 4 weeks after
vaccination with PPSV23 were numerically comparable in both
primary vaccination and revaccination groups (Table 3 and Fig. 1).
3.3. Safety
Incidence rates of injection-site and systemic AEs occurring after
PPSV23 vaccination in each vaccination group are summarized in
Table 4. More subjects in the revaccination group reported at least
one injection-site AE than those in the primary vaccination group
(70.2% and 50.6%, respectively). Severe injection-site pain, ery-
thema and swelling of >10 cm (4 in.) were reported by 3.7%, 6.2%,
and 4.3%, respectively, in the revaccination group, and no subject
reported a severe injection-site AE in the primary vaccination group.
No differences were observed between the 2 vaccination groups in
the incidence rates of systemic AEs: 26.1% in the revaccination
group and 19.8% in the primary vaccination group. FeverP37.5 C
to <38.0 C, P38.0 C to <38.5 C, and P38.5 C were reported by
4.3% (7/161), 1.9% (3/161), and 0.6% (1/161), respectively in the
revaccination group, and fever P37.5 C to <38.0 C was reported
by 1.2% (1/81) in the primary vaccination group. Other common
systemic AEs in both vaccination groups were diarrhoea, malaise,
nasopharyngitis, and dizziness. No deaths or vaccine-related AEs
leading to study discontinuation occurred during the study. Four
SAEs were reported in the revaccination group. Two of these events
(mild pyrexia on Day 2 postvaccination; severe herpes virus infec-
tion on Day 7 postvaccination) were assessed as vaccine-related
AEs by the study investigators.4. Discussion
Our study demonstrated that serotype-specific IgG GMCs to
serotypes 3, 6B, and 23F measured at 4 weeks after revaccination
with PPSV23 were significantly higher than those measured imme-
diately before revaccination. Increases in IgG GMCs from baseline
to postvaccination were also observed for 11 additional vaccine
serotypes that were tested by Pn ECL assay in this study. In
addition to IgG responses, several studies have emphasized the
need to measure functional OPA antibodies as an important biolog-
Table 2
IgG GMCs and GMFRs before and after vaccination with PPSV23 in the revaccination and primary vaccination groups.
Revaccination group (N = 160–161) Primary vaccination group (N = 81)
Baseline 4 weeks after vaccination Fold rise at
4 weeks after
vaccination
Baseline 4 weeks after vaccination Fold rise at 4 weeks
after vaccination
Serotype GMC (lg/mL) (95% CI) GMC (lg/mL) (95% CI) GMFR (95% CI) GMC (lg/mL) (95% CI) GMC (lg/mL) (95% CI) GMFR (95% CI)
1 0.95 (0.78, 1.16) 3.31 (2.69, 4.06) 3.47 (2.96, 4.07) 0.43 (0.33, 0.56) 4.30 (3.14, 5.89) 10.01 (7.67, 13.07)
3 0.14 (0.12, 0.16) 0.49 (0.41, 0.59) 2.72 (2.35, 3.14) 0.09 (0.07, 0.11) 0.54 (0.42, 0.69) 4.01 (3.17, 5.08)
4 0.27 (0.22, 0.34) 0.63 (0.50, 0.79) 2.25 (1.99, 2.53) 0.15 (0.12, 0.18) 0.90 (0.67, 1.22) 5.84 (4.56, 7.47)
5 1.32 (1.09, 1.61) 2.57 (2.08, 3.18) 1.94 (1.74, 2.17) 0.65 (0.53, 0.80) 2.42 (1.83, 3.20) 3.73 (2.92, 4.76)
6B 0.89 (0.71, 1.12) 2.10 (1.65, 2.68) 2.27 (2.02, 2.55) 0.33 (0.24, 0.44) 2.08 (1.41, 3.07) 5.83 (4.41, 7.69)
7F 0.85 (0.67, 1.08) 2.54 (2.02, 3.21) 2.85 (2.52, 3.24) 0.34 (0.25, 0.46) 3.36 (2.29, 4.92) 8.92 (6.83, 11.64)
9V 0.89 (0.73, 1.09) 2.07 (1.69, 2.54) 2.33 (2.11, 2.58) 0.38 (0.28, 0.50) 2.55 (1.86, 3.49) 6.65 (5.29, 8.37)
14 3.76 (2.97, 4.77) 6.37 (5.02, 8.09) 1.68 (1.49, 1.90) 1.30 (0.96, 1.76) 5.34 (3.63, 7.84) 4.07 (3.09, 5.37)
18C 1.75 (1.44, 2.13) 4.15 (3.41, 5.05) 2.36 (2.09, 2.66) 0.65 (0.50, 0.84) 4.98 (3.72, 6.66) 7.71 (6.11, 9.73)
19A 2.15 (1.78, 2.59) 4.43 (3.57, 5.51) 2.07 (1.85, 2.31) 1.47 (1.15, 1.88) 6.61 (4.79, 9.12) 4.49 (3.53, 5.71)
19F 1.59 (1.27, 1.98) 4.04 (3.16, 5.18) 2.53 (2.24, 2.85) 0.61 (0.46, 0.80) 3.90 (2.83, 5.38) 6.25 (5.02, 7.77)
22F 0.55 (0.44, 0.68) 1.59 (1.26, 1.99) 2.79 (2.42, 3.22) 0.21 (0.16, 0.26) 1.15 (0.83, 1.58) 4.94 (3.82, 6.39)
23F 1.36 (1.08, 1.72) 3.34 (2.62, 4.26) 2.40 (2.12, 2.72) 0.50 (0.37, 0.68) 3.23 (2.18, 4.78) 6.11 (4.65, 8.02)
33F 4.81 (3.90, 5.93) 9.95 (8.25, 12.00) 2.06 (1.86, 2.28) 1.40 (1.11, 1.76) 12.84 (9.52, 17.33) 9.11 (7.19, 11.56)
6Aa 0.89 (0.71, 1.12) 1.79 (1.40, 2.28) 1.95 (1.75, 2.18) 0.49 (0.35, 0.67) 1.81 (1.25, 2.63) 3.52 (2.69, 4.61)
IgG, immunoglobulin G; GMC, geometric mean concentration; GMFR, geometric mean fold rise; PPSV23, 23-valent pneumococcal polysaccharide vaccine; CI, confidence
interval.
a Serotype 6A is not included in PPSV23 vaccine serotype.
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in the elderly [20,21]. Results from our study showed that
serotype-specific OPA GMTs for 6 vaccine serotypes were higher
at 4 weeks after revaccination than immediately before PPSV23
revaccination. IgG and OPA fold-rises for all serotypes were signif-
icantly lower following revaccination than primary vaccination
with PPSV23 (nominal P < 0.05). This is likely due to the presence
of pre-existing anti-pneumococcal antibodies and is consistent
with previous findings [12,14].
To our knowledge, our study is the first study that has measured
IgG concentrations for serotype 22F, and 33F and OPA titer for
serotype 22F following receipt of a second dose of PPSV23 in the
elderly Japanese individuals. Of interest is the increase in bothFig. 1. Radar charts of GMCs of serotype-specific IgG for 14 serotypes (A) and GMTs of se
groups. Red dotted line: Revaccination group at baseline; Blue dotted line: Primary vaccin
vaccination; Blue solid line: Primary vaccination group at 4 weeks after PPSV23 va
opsonophagocytic killing activity; GMTs, geometric mean titers; PPSV23, 23-valent pneIgG GMC and OPA GMT to serotype 3, as it has been identified as
the most common cause of IPD in Japanese adults [11]. Although
serotype 6A is not contained in PPSV23, IgG GMC for serotype 6A
increased following vaccination with PPSV23 in both groups,
which indicates possible cross-protection afforded by serotype 6B
included in PPSV23 against pneumococcal disease caused by
serotype 6A.
The matching of subjects’ key baseline characteristics (i.e. age,
gender, and underlying medical conditions) between the primary
and revaccination groups were performed so as to evaluate the
serotype-specific immune responses as well as safety in both
vaccination groups excluding the potential factors associated with
the immune responses [22,23]. Although not superior to levelsrotype-specific OPA for 6 serotypes (B) in the revaccination and primary vaccination
ation group at baseline; Red solid line: Revaccination group at 4 weeks after PPSV23
ccination. IgG, immunoglobulin G; GMCs, geometric mean concentrations; OPA,
umococcal polysaccharide vaccine.
Table 3
OPA GMTs and GMFRs before and after vaccination with PPSV23 in the revaccination and primary vaccination groups.
Revaccination group (N = 158–159) Primary vaccination group (N = 78–79)
Baseline 4 weeks after vaccination Fold rise at 4 weeks
after vaccination
Baseline 4 weeks after vaccination Fold rise at 4 weeks
after vaccination
Sero type GMT (95% CI) GMT (95% CI) GMFR (95% CI) GMT (95% CI) GMT (95% CI) GMFR (95% CI)
3 28.83 (23.58, 35.24) 163.91 (138.72, 193.68) 4.96 (4.26, 5.76) 20.41 (15.33, 27.18) 205.18 (162.38, 259.28) 8.32 (6.50, 10.65)
4 27.89 (21.07, 36.91) 184.64 (139.89, 243.70) 5.25 (4.14, 6.66) 15.49 (10.58, 22.66) 351.92 (256.04, 483.70) 15.66 (11.08, 22.11)
6B 186.24 (138.53, 250.38) 602.76 (473.47, 767.36) 3.00 (2.51, 3.59) 47.94 (29.18, 78.77) 746.02 (523.40, 1063.33) 13.55 (9.27, 19.81)
14 369.40 (284.32, 479.94) 753.58 (592.77, 958.00) 2.03 (1.75, 2.35) 119.21 (75.76, 187.60) 640.15 (418.65, 978.83) 5.18 (3.60, 7.45)
22F 82.68 (59.87, 114.19) 576.15 (451.40, 735.37) 5.81 (4.52, 7.47) 31.43 (18.81, 52.52) 436.97 (289.08, 660.52) 10.31 (6.44, 16.51)
23F 110.56 (81.76, 149.50) 318.73 (238.34, 426.24) 2.55 (2.05, 3.16) 24.30 (15.43, 38.28) 320.39 (206.75, 496.49) 9.77 (6.58, 14.51)
OPA, opsonophagocytic killing activity; GMT, geometric mean titer; GMFR, geometric mean fold rise; PPSV23, 23-valent pneumococcal polysaccharide vaccine; CI, confidence
interval.
Median time interval between 1st and 2nd dose of PPSV23 in the revaccination group was 7 years.
Table 4
Injection-site and systemic AEs after vaccination with PPSV23.
Revaccination group (N = 161) Primary vaccination group (N = 81) Difference in %
n (%) n (%) Estimate (95% CI)
Any injection-site AE 113 (70.2%) 41 (50.6%) 19.6 (6.6, 32.3)
Injection-site pain
Any 101 (62.7) 38 (46.9) 15.8 (2.6, 28.7)
Mild 77 (47.8) 34 (42.0)
Moderate 18 (11.2) 4 (4.9)
Severe 6 (3.7) 0 (0.0)
Injection-site erythema (cm)
Any 57 (35.4) 12 (14.8) 20.6 (9.1, 30.7)
0 to 65 34 (21.1) 10 (12.3)
5 to 610 13 (8.1) 2 (2.5)
>10 10 (6.2) 0 (0.0)
Injection-site swelling (cm)
Any 62 (38.5) 14 (17.3) 21.2 (9.3, 31.7)
0 to 65 34 (21.1) 12 (14.8)
5 to 610 21 (13.0) 2 (2.5)
>10 7 (4.3) 0 (0.0)
Systemic adverse events 42 (26.1) 16 (19.8) 6.3 (5.4, 16.8)
Fever P37.5 C to <38.0 C 7 (4.3) 1 (1.2)
P38.0 C to <38.5 C 3 (1.9) 0 (0.0)
P38.5 C 1 (0.6) 0 (0.0)
Diarrhoea 3 (1.9) 2 (2.5)
Malaise 4 (2.5) 0 (0.0)
Nasopharyngitis 4 (2.5) 1 (1.2)
Dizziness 0 (0.0) 2 (2.5)
No deaths or discontinuation due to vaccine-related severe adverse events.
AE, adverse event; PPSV23, 23-valent pneumococcal polysaccharide vaccine; CI, confidence interval.
The size of injection-site erythema and swelling were measured by inch. The inch unit were converted to the centimeter (cm).
K. Kawakami et al. / Vaccine 34 (2016) 3875–3881 3879achieved after primary vaccination, immune responses increased
from baseline to postvaccination after a second dose of PPSV23
administered at least 5 years after the initial dose, and the magni-
tude of the elicited IgG concentrations and OPA titers reached
levels comparable to those observed in the primary vaccination
group. Though immune responses after the second dose of PPSV23
are reported to be lower than those observed after the initial dose
in another study [24], no evidence of hyporesponsiveness follow-
ing PPSV23 revaccination was observed for the serotypes evaluated
in our study.
The analyses of subgroups by comorbidities in the revaccination
group suggest that baseline serotype-specific IgG GMCs were not
affected by the presence of underlying comorbidities; however
baseline serotype-specific OPA titers for serotypes 6B, 14, and
22F in subjects with comorbidities (chronic heart disease, chronic
lung disease, and diabetes mellitus) tended to be lower than those
in subjects without comorbidities (supplementary data, Tables S1and S3, Figs. S1A and S2A). Increases in IgG GMCs and OPA GMTs
after revaccination with PPSV23 were also observed in subjects
with comorbidities (supplementary data, Tables S2 and S4,
Figs. S1B and S2B). This observation is consistent with the report
in the Japanese elderly patients with chronic lung disease [17].
Therefore, we demonstrated that revaccination with PPSV23 in
elderly subjects could induce the immune responses regardless
of comorbidities such as chronic heart disease, chronic lung
disease, and diabetes mellitus.
The analyses of subgroups by age in the revaccination group
showed no differences in baseline IgG GMCs and OPA GMTs
between subjects aged 70–79 years and subjects aged 80–89 years.
Revaccination with PPSV23 in both subgroups led to comparable
increases in serotype-specific IgG GMCs and OPA GMTs for all
serotypes tested (supplementary data, Tables S5 and S6, Fig. S3).
These data suggest that revaccination with PPSV23 at least 5 years
3880 K. Kawakami et al. / Vaccine 34 (2016) 3875–3881after the initial dose induces satisfactory immune responses even
in older Japanese adults.
The safety analysis showed that the incidence of injection-site
AEs was significantly higher in the revaccination group than in
the primary vaccination group. However, most AEs were mild to
moderate in intensity, and resolved within 5 days of onset without
any medical treatment. Incidence rates of systemic AEs were
comparable in the revaccination and primary vaccination groups.
Our study results are consistent with those observed in previous
studies evaluating safety following revaccination with PPSV23
[12,17,25].
Although enrolling more subjects than previous studies of
PPSV23 revaccination in the Japanese elderly, the sample size of
our study was still limited to 161 revaccinated subjects, and
serotype-specific antibodiesweremeasured only for a subset of vac-
cine serotypes, 14 serotypes for IgG GMCs and 6 serotypes for OPA
GMTs. The clinical benefits of the observed increases in antibody
levels following primary or revaccination with PPSV23 cannot be
clearly established, as thresholds of serotype-specific antibody
concentrations and OPA titers that correlate with prevention of
pneumococcal disease in adults have not been established.
Additional studies on the relationship between levels of vaccine-
induced antibodies achieved following revaccination with PPSV23
and prevention of pneumococcal disease need further evaluation.5. Conclusions
The results of the present study showed that revaccination with
PPSV23 was well tolerated and associated with an increase in IgG
concentrations and OPA titers in the Japanese elderly P70 years
of age who had received PPSV23 at least 5 years before. The levels
of serotype-specific IgG GMCs and OPA GMTs measured in
revaccinated subjects were generally comparable to those
observed following primary vaccination for the serotypes tested.
Currently, Japan has a rapidly growing elderly population, wherein
1 in 5 people are agedP70 years. The findings of the present study
are important clinical evidence that a second dose of PPSV23 can
be safely administered and elicit favorable immune responses for
the continued prevention of pneumococcal disease in the elderly
population.Funding
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